The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.
von Palffy S, Thorsson H, Peña-Martínez P, Puente-Moncada N, Sandén C, Blom AM, Henningsson R, Juliusson G, King B, Landberg N, Lazarevic V, Orsmark-Pietras C, Rissler M, Rissler V, Ågerstam H, Järås M, Lilljebjörn H, Fioretos T.
von Palffy S, et al. Among authors: pena martinez p.
Blood Adv. 2023 Apr 11;7(7):1204-1218. doi: 10.1182/bloodadvances.2022007682.
Blood Adv. 2023.
PMID: 36383712
Free PMC article.